Shares of Cassava Sciences (SAVA) were halted ahead of the company reporting that the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD did not meet each of the prespecified co-primary, secondary and exploratory biomarker endpoints and that Cassava will discontinue all efforts to develop simufilam for Alzheimer’s disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Cassava Sciences’ Alzheimer’s Drug Trials Fall Short, Neutral Rating Maintained Amid Uncertainties
- Cassava Sciences Amends Bonus Plan After Court Settlement
- H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal
- Cassava Sciences Reports 2024 Financial Results and Strategic Updates
- Cassava Sciences reports Q4 EPS (57c) vs (50c) last year